Last updated: February 22, 2026
What Is the Drug QC MUCUS DM MAX ER?
QC MUCUS DM MAX ER is an extended-release combination medication containing dextromethorphan, guaifenesin, and phenylephrine. It is marketed for symptomatic relief of cough, chest congestion, and nasal congestion associated with upper respiratory infections.
Market Overview
Therapeutic Category and Indications
- Therapeutic class: Expectorants and cough suppressants.
- Indications: Symptom relief in acute upper respiratory conditions, including cough, mucus, and nasal congestion.
- Target population: Adults and children over 12 years old.
Competition & Market Size
The combined demand for OTC cough and cold remedies in the U.S. reached $4.8 billion in 2022, according to IQVIA.[1] The segment for combination products similar to QC MUCUS DM MAX ER accounts for approximately 20% of this market, roughly $960 million.
Major competitors include:
- Mucinex DM (guaifenesin and dextromethorphan)
- Robitussin DM
- Delsym (dextromethorphan)
- Sudafed PE (phenylephrine-based formulations)
Market Dynamics
- Seasonality: Peak sales occur during cold and flu season (Q4 to Q1).
- Consumer trends: Increasing preference for extended-release and combination therapies expected to drive growth.
- Regulatory factors: OTC switching status influences sales potential; current status of QC MUCUS DM MAX ER is prescription-only or OTC varies by jurisdiction.
Pricing Landscape
Existing Market Prices
| Product |
Typical Retail Price (USD) |
Packaging and Dosage |
Formulation |
| Mucinex DM |
$15 for 20 tablets |
600 mg guaifenesin + 30 mg dextromethorphan |
Extended-release tabs |
| Robitussin DM |
$8 for 8 oz syrup |
100 mg guaifenesin + 10 mg dextromethorphan |
Syrup |
| Delsym |
$12 for 4 oz |
30 mg dextromethorphan |
Extended-release liquid |
| Sudafed PE |
$9 for 20 caplets |
10 mg phenylephrine |
Caplet |
Projected Pricing for QC MUCUS DM MAX ER
Prices depend on regulatory approval status, packaging size, and distribution channels. Based on similar products, the expected retail price could range:
- Extended-release tablets (30-count): $16-$20
- Packaged as a maximum strength formula: Premium pricing up to $22
- Wholesale acquisition cost (WAC): Around 60% of retail, approximately $10-$13 per package
Pricing Trends
- Premium positioning: Products with extended-release mechanisms command a higher price.
- Generic entry: Will exert downward pressure on price if generics are approved.
- Formulation improvements: Adding ingredients or changing delivery systems can impact pricing strategies.
Regulatory Status and Its Impact on Market Entry
- OTC status: OTC availability drives volume but prompts price competition.
- Prescription status: Prescriptions could limit consumer access, reducing volume but potentially maintaining higher prices.
- Regulatory approvals: Pending FDA approval, or similar regulatory bodies internationally, influence initial market penetration and pricing.
Price Projection Summary
| Year |
Projected Retail Price (USD) |
Assumptions |
| 2023 |
$16-$20 |
Pending regulatory approval; initial launch at mid-tier price. |
| 2024 |
$15-$19 |
Competitors enforce price competition; price stabilization. |
| 2025 |
$14-$18 |
Increased generic competition; price erosion continues. |
Market Entry Considerations
- Pricing flexibility: Maintaining price premium during initial launch to recoup R&D costs.
- Formulation diversification: Offering multiple pack sizes or formulations to target different segments.
- Distribution channels: Expanding pharmacy, online, and retail presence to optimize volume and margin.
Key Takeaways
- The market for cough and cold combination products like QC MUCUS DM MAX ER is highly competitive, with a total market size of approximately $960 million in the U.S.
- The product’s price point is expected to initially range from $16 to $20 retail per package, influenced by formulation strength, regulatory status, and competitor pricing.
- Long-term pricing will likely decline with generic entry, but premium positioning can persist with formulation differentiation.
- Market dynamics are heavily seasonal, with significant volume spikes during cold and flu seasons.
- Strategic marketing and distribution expansion will be critical for capturing market share and optimizing revenues.
FAQs
1. When can QC MUCUS DM MAX ER reach the market?
Pending regulatory approval, likely within 12-24 months after submission.
2. How will generic competition impact the price?
The entry of generics typically reduces the retail price by 20-40%, depending on market share and brand loyalty.
3. What are the main regulatory hurdles?
FDA approval depends on demonstrating bioequivalence, safety, and efficacy, along with meeting manufacturing standards.
4. Can OTC reclassification occur post-approval?
Yes, with FDA review and application, OTC status can be granted or withdrawn, affecting market reach and pricing.
5. What are the key drivers for market growth?
Increased demand during cold seasons, consumer preference for extended-release formulations, and expanded distribution channels.
Sources
[1] IQVIA. (2022). U.S. OTC Cold and Cough Market Data.
